Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Serum Albumin in Healthy Subjects
NCT05179265Phase 1Completed
- Sponsor
- Protogen
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human serum albumin in ascites (2 arms), sponsored by Protogen. Primary endpoints: Treatment-Emergent Adverse Events at 99 days and Serious Adverse Events at 99 days. Started Mar 2021; status: completed.
02
Drugs
recombinant human serum albumin
03
Conditions
ascites
Beyond the preview
Go deeper on NCT05179265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179265.